Acrylamide-induced effects on general and neurospecific cellular functions during exposure and recovery

Cell Biology and Toxicology

Volumn 19, Issue 1, 2003, Pages 43-51

  Nordin Andersson, M ^a,b   Walum, E ^a,c   Kjellstrand, P ^b   Forsby, Anna ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b Gambro AB   (Sweden)

^c BIOVITRUM AB   (Sweden)

Author keywords

Acrylamide; Calcium; Neurotoxicity; Recovery; SH SY5Y

Indexed keywords

ACRYLAMIDE; CALCIUM; CALPEPTIN; CARBACHOL;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; CYTOTOXICITY; HUMAN; HUMAN CELL; NEURITE; NEUROBLASTOMA CELL; NEUROPATHY; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION;

ACRYLAMIDE; CALCIUM; CARBACHOL; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEURITES; NEUROBLASTOMA; NEUROTOXINS; PROTEIN BIOSYNTHESIS; TUMOR CELLS, CULTURED;

EID: 0037294942     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022017731328     Document Type: Article

References (38)

1. Atterwill CK, Bruinink A, Drejer J et al. In vitro neurotoxicity testing. The report and recommendations of ECVAM Workshop 3. ATLA. 1994;22:350-62.
2. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 1978;38:3751-7.
3. 2+ stores and cell responsiveness. Am J Physiol. 1993;264:367-87.
4. Bottenstein J, Sato G. Growth of rat neuroblastoma cell line in serum-free supplemented media. Proc Natl Acad Sci USA. 1979;76:517-24.
5. Calleman CJ. The metabolism and pharmacokinetics of acrylamide: implications for mechanisms of toxicity and human risk estimation. Drug Metab Rev. 1996;28:527-90.
6. Cavanagh JB. The significance of the "dying back" process in the experimental and human neurological disease. Int Rev Exp Pathol. 1964;3:219-67.
7. Cavanagh JB. The pathokinetics of acrylamide intoxication. Reassessment of the problem. Neuropathol Appl Neurobiol. 1982;8:315-36.
8. Crofton KM, Padilla S, Tilson HA, Anthony DC, Raymer JH, MacPhal RC. The impact of dose rate on the neurotoxicity of acrylamide: the interaction of administered dose, target tissue concentrations, tissue damage and functional effects. Toxicol Appl Pharmacol. 1996;139:163-76.
9. DeJongh J, Nordin-Andersson M, Ploeger BA, Forsby A. Estimation of systemic toxicity of acrylamide by integration of in vitro toxicity data with kinetic simulations. Toxicol Appl Pharmacol. 1999;158:261-8.
10. Faddis BT, Hasbani MJ, Goldberg MP. Calpain activation contributes to dendritic remodeling after brief excitotoxic injury in vitro. J Neurosci. 1997;17:951-9.
11. Forsby A, Pilli F, Bianchi V, Walum E. Determination of critical neurotoxic concentrations in human neuroblastoma (SH-SY5Y) cells. ATLA. 1995;23:800-11.
12. Fullerton PM. Electrophysiological observations on peripheral nerves in acrylamide poisoning in man. J Neurol Neurosurg Psychiatry. 1969;32:186-92.
13. Hamblin DO. The toxicity of acrylamide. A preliminary report. In: Hommage au Doyen. Paris; 1956:195-9.
14. 2+ and inositol 1,4,5-trisphophate mass in human neuroblastoma cell line, SH-SY5Y. Biochem J. 1990;265:555-62.
15. Le Quesne PM. Acrylamide. In: Spencer PS, Schaumberg HH, eds, Experimental and clinical neurotoxicology. Baltimore: Williams and Wilkins; 1980:309-25
16. Lehning EJ, LoPachin RM. Changes in Na-K ATPase and protein kinase C activities in peripheral nerve of acrylamide treated rats. J Toxicol Environ Health. 1994;42:331-42.
17. LoPachin RM, Lehning EJ. Acrylamide-induced distal axon degeneration: a proposed mechanism of action. Neurotoxicology. 1994;12:247-60.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-75.
19. McConkey DJ, Orrenius S. The role of calcium in the regulation of apoptosis. J Leukoc Biol. 1996;59:775-83.
20. Nordin-Andersson M, Forsby A, Heldring N, DeJongh J, Kjellstrand P, Walum E. Neurite degeneration in differentiated human neuroblastoma cells. Toxicol in Vitro. 1998;12:557-60.
21. Nyberg E, Walum E. On the application of cultured neuronal cell lines in neurotoxicological studies: implications of acrylamide-induced neurite disintegration. ATLA. 1984;11:194-203.
22. Odland L, Romert L, Clemedson C, Walum E. Glutathione content, glutathione transferase activity and lipid peroxidation in acrylamide-treated neuroblastoma N1E115 cells. Toxicol in Vitro. 1994;8:263-7.
23. Pentreath VW. Structure, function and toxicity in nervous tissue. In: Pentreath VW, ed. Neurotoxicology in vitro. Philadelphia: Taylor and Francis; 1999:17-41.
24. Påhlman S, Ruusala AI, Abrahamsson L, Mattsson MEK, Esscher T. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ. 1984;14:135-44.
25. Pörn-Ares MI, Ares MPS, Orrenius S. Calcium signalling and the regulation of apoptosis. Toxicol in Vitro. 1998;12:539-43.
26. Rami A, Ferger D, Krieglstein J. Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity. Neurosci Res. 1997;27:93-7.
27. Schotman P, Gipon L, Jennekens FGI, Gispen WH. Polyneuropathies and CNS proteins metabolism, III. Changes in protein synthesis rate induced by acrylamide. J Neuropathol Exp Neurol. 1978;37:820-37.
28. Schumacher PA, Siman RG, Fehlings MG. Pretreatment with calpain inhibitor CEP-4143 inhibits calpain I activation and cytoskeletal degradation, improves neurological function, and enhances axonal survival after traumatic spinal cord injury. J Neurochem. 2000;74:1646-55.
29. Sickles DW. Toxic neurofilamentous axonopathies and fast anterograde axonal transport. I. The effects of single doses of acrylamide on the rate and capacity of transport. Neurotoxicology. 1989;10:91-101.
30. Smith EA, Oehme FW. Acrylamide and polyacrylamide: a review of production, use, environmental fate and neurotoxicity. Rev Environ Health. 1991;9:215-28.
31. Spencer PS, Schaumburg HH. A review of acrylamide neurotoxicity. Part I. Properties, uses and human exposure. J Can Sci Neurol. 1974;1:143-50
32. Spencer PS, Schaumburg HH. Ultrastructural studies of the dying-back process. III. The evolution of experimental peripheral giant axonal degeneration. J Neuropathol Exp Neurol. 1977a;36:276-99.
33. Spencer PS, Schaumburg HH. Ultrastructural studies of the dying-back process. IV. Differential vulnerabilities of PNS and CNS fibers in experimental central-peripheral distal axonopathies. J Neuropathol Exp Neurol. 1977b;36:300-20.
34. Stacey G, Vivani B. Cell culture models for neurotoxicity. Cell Biol Toxicol. 2001;17:319-34.
35. Tilson HA. The neurotoxicity of acrylamide: an overview. Neurobehav Toxicol Teratol. 1981;3:445-61.
36. Veronesi B. In vitro screening batteries for neurotoxicants. Neurotoxicology. 1992;13:185-96.
37. Walum E, Varnbo I, Peterson A. A multiple cell-culture toxicity test system based on neuroblastoma C1300 cells and differentiated primary cultures of brain, muscle, heart and liver cells. Food Chem Toxicol. 1986;24:567-8.
38. Walum E, Odland L, Romert L et al. Biochemical approaches to neurotoxicology in vitro: Attempts to develop a test system for chemically induced axonopathy. In: Proceedings of the Conference on In Vitro Toxicology: In Vitro Methods in Toxicology, 12. London: Academic Press; 1992:237-51.